Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Puma Biotechnology Inc (PBYI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: PBYI (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 57.6% | Avg. Invested days 34 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 156.04M USD | Price to earnings Ratio 5.1 | 1Y Target Price 4.33 |
Price to earnings Ratio 5.1 | 1Y Target Price 4.33 | ||
Volume (30-day avg) 452615 | Beta 1.33 | 52 Weeks Range 2.23 - 6.05 | Updated Date 03/31/2025 |
52 Weeks Range 2.23 - 6.05 | Updated Date 03/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.58 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 13.14% | Operating Margin (TTM) 22.62% |
Management Effectiveness
Return on Assets (TTM) 8.72% | Return on Equity (TTM) 41.6% |
Valuation
Trailing PE 5.1 | Forward PE 7.3 | Enterprise Value 128894908 | Price to Sales(TTM) 0.68 |
Enterprise Value 128894908 | Price to Sales(TTM) 0.68 | ||
Enterprise Value to Revenue 0.56 | Enterprise Value to EBITDA 2.68 | Shares Outstanding 49610800 | Shares Floating 42095259 |
Shares Outstanding 49610800 | Shares Floating 42095259 | ||
Percent Insiders 15.35 | Percent Institutions 59.27 |
Analyst Ratings
Rating 3 | Target Price 4.33 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold 1 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Puma Biotechnology Inc
Company Overview
History and Background
Puma Biotechnology, Inc. is a biopharmaceutical company founded in 2011, focused on the development and commercialization of innovative products to enhance cancer care. Its initial focus was on acquiring and developing neratinib, a drug developed by Wyeth that Puma further developed and commercialized.
Core Business Areas
- Oncology: Focuses on the development and commercialization of targeted therapies for cancer treatment, primarily centered around the drug neratinib (Nerlynx).
Leadership and Structure
Alan H. Auerbach is the Chairman, President and Chief Executive Officer. The company has a typical biopharmaceutical organizational structure with departments covering research and development, commercial operations, regulatory affairs, and finance.
Top Products and Market Share
Key Offerings
- Nerlynx (neratinib): Nerlynx is an oral tyrosine kinase inhibitor approved for extended adjuvant treatment of adult patients with early-stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy. Competitors include other HER2-targeted therapies like trastuzumab (Herceptin) by Roche/Genentech, pertuzumab (Perjeta) by Roche/Genentech, and T-DM1 (Kadcyla) by Roche/Genentech. Exact market share data is difficult to pinpoint, but Nerlynx is a niche product within the broader HER2-positive breast cancer market.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition. The oncology segment is driven by the increasing prevalence of cancer, advancements in targeted therapies, and the growing demand for personalized medicine.
Positioning
Puma Biotechnology occupies a niche position within the oncology market, specifically targeting HER2-positive breast cancer. Its competitive advantage lies in offering an oral, extended adjuvant therapy option for patients who have already completed trastuzumab treatment.
Total Addressable Market (TAM)
The TAM for HER2-positive breast cancer therapies is substantial, estimated in the billions of dollars. Puma Biotechnology's Nerlynx addresses a segment of this market, focusing on extended adjuvant treatment. The exact TAM relevant to Nerlynx depends on the number of eligible patients and pricing strategies. Puma's positioning within this TAM is that of a company offering a treatment option after the initial treatment with Herceptin.
Upturn SWOT Analysis
Strengths
- Approved drug (Nerlynx)
- Targeted therapy
- Oral administration
- Experienced management team
Weaknesses
- Sole product dependency
- Competition from established therapies
- Side effect profile of Nerlynx (diarrhea)
- High marketing and sales expenses relative to revenue
Opportunities
- Expansion into new indications
- Partnerships and collaborations
- Geographic expansion
- Improved formulations or delivery methods
Threats
- Competition from biosimilars
- Patent expirations
- Regulatory hurdles
- Clinical trial failures
- Pricing pressures
Competitors and Market Share
Key Competitors
- ROSE.SW
- NVS
- PFE
- LLY
Competitive Landscape
Puma Biotechnology faces intense competition from established pharmaceutical companies with broader portfolios and greater resources. Its success depends on differentiating Nerlynx through clinical data, patient support programs, and strategic partnerships.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been tied to the sales performance of Nerlynx. The growth trajectory has been variable, influenced by competition, market access, and pricing.
Future Projections: Future growth projections depend on the success of Nerlynx in existing indications, potential expansion into new indications, and strategic partnerships. Analyst estimates would need to be consulted for specific projections.
Recent Initiatives: Recent initiatives would include efforts to expand the use of Nerlynx, improve its side effect profile, and explore new indications.
Summary
Puma Biotechnology's strength lies in its approved drug, Nerlynx, which targets a specific segment of HER2-positive breast cancer. However, the company's reliance on a single product, intense competition, and the side effect profile of Nerlynx pose significant challenges. Future success hinges on expanding the drug's indications and managing competition effectively, but the company's fundamentals are challenged by cash flow issues.
Similar Companies
- ROSE.SW
- NVS
- AZN
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (where available)
- Industry Publications
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not financial advice. Market share data is approximate and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Puma Biotechnology Inc
Exchange NASDAQ | Headquaters Los Angeles, CA, United States | ||
IPO Launch date 2012-04-24 | Founder, Chairman, President, CEO & Secretary Mr. Alan H. Auerbach | ||
Sector Healthcare | Industry Biotechnology | Full time employees 172 | |
Full time employees 172 | |||
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.